Foreign-Trade Zone (FTZ) 46, Notification of Proposed Production Activity; Patheon API, Inc., (Pharmaceutical Products); Cincinnati, Ohio

---
identifier: "/us/fr/2026-04949"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Foreign-Trade Zone (FTZ) 46, Notification of Proposed Production Activity; Patheon API, Inc., (Pharmaceutical Products); Cincinnati, Ohio"
title_number: 0
title_name: "Federal Register"
section_number: "2026-04949"
section_name: "Foreign-Trade Zone (FTZ) 46, Notification of Proposed Production Activity; Patheon API, Inc., (Pharmaceutical Products); Cincinnati, Ohio"
positive_law: false
currency: "2026-03-13"
last_updated: "2026-03-13"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Commerce Department"
document_number: "2026-04949"
document_type: "notice"
publication_date: "2026-03-13"
agencies:
  - "Commerce Department"
  - "Foreign-Trade Zones Board"
fr_citation: "91 FR 12341"
fr_volume: 91
docket_ids:
  - "B-28-2026"
---


#  Foreign-Trade Zone (FTZ) 46, Notification of Proposed Production Activity; Patheon API, Inc., (Pharmaceutical Products); Cincinnati, Ohio

Patheon API, Inc., submitted a notification of proposed production activity to the FTZ Board (the Board) for its facilities in Cincinnati, Ohio within Subzone 46K. The notification conforming to the requirements of the Board's regulations (15 CFR 400.22) was received on March 9, 2026.

Pursuant to 15 CFR 400.14(b), FTZ production activity would be limited to the specific foreign-status material(s)/component(s) and specific finished product(s) described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board's website—accessible via *www.trade.gov/ftz.* The proposed finished product(s) and material(s)/component(s) would be added to the production authority that the Board previously approved for the operation, as reflected on the Board's website.

The proposed finished product is agonist treatment drug for ulcerative colitis (API Ono-6414HY) (duty-free).

The proposed foreign-status material/component is 2-{[2-({2-[(2R)-2-{(1E,3S)-3-Hydroxy-8-[(pyridin-2-yl)sulfanyl]oct-1-en-1-yl}-5-oxopyrrolidin-1-yl]ethyl}sulfanyl)-1,3-thiazole-4-carbonyl]amino}ethane-1-sulfonic acid monohydrate, active pharmaceutical ingredient (duty rate 6.5%).

The request indicates that the material/component is subject to duties under section 301 of the Trade Act of 1974 (section 301), depending on the country of origin. The applicable section 301 decisions require subject merchandise to be admitted to FTZs in privileged foreign status (19 CFR 146.41).

Public comment is invited from interested parties. Submissions shall be addressed to the Board's Executive Secretary and sent to: *[email protected].* The closing period for their receipt is April 22, 2026.

A copy of the notification will be available for public inspection in the “Online FTZ Information System” section of the Board's website.

For further information, contact Christopher Wedderburn at *[email protected].*

Dated: March 10, 2026.

Elizabeth Whiteman,

Executive Secretary.